Spliced to kill: RNA mis-splicing derived cancer neoantigens.

Abstract

One of the major challenges in using neoantigen-based approaches in cancer treatment is the identification of cancer-specific neoantigens, particularly those that are shared by patients. In a recent report, Kim et al. uncover a novel source of cancer neoantigens in splicing factor mutant myeloid malignancies. These mis-spliced neoantigens offer new opportunities for engineered TCR-T cell therapies and neoantigen-based vaccines.